GlaxoSmithKline: Amyloidosis trials

The registry lists 10 Amyloidosis studies with GlaxoSmithKline as lead sponsor. 1 are open to participants now and 3 have results posted.

Phase 1 7Phase 2 3Phase 3 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) AmyloidosisRecruitingNCT07224672Phase 2
• Biodistribution of 89Zirconium-labelled GSK2398852 Using PET ImagingTerminatedNCT03417830Phase 1Results posted
• Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698TerminatedNCT03044353Phase 2Results posted
• A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic AmyloidosisTerminatedNCT02603172Phase 1Results posted
• Pro-arrhythmic Potential of GSK3039294 in Healthy SubjectsWithdrawnNCT03567499Phase 1
• Phase 1 Study of GSK2315698 in Healthy Japanese SubjectsCompletedNCT02953808Phase 1
• A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic AmyloidosisCompletedNCT01777243Phase 1
• SAP Depleter Dose Assessment Study in PatientsCompletedNCT01406314Phase 1
• SAP Depleter Dose Escalation Study in Healthy VolunteersCompletedNCT01323985Phase 1
• Study of the Safety and Efficacy of NC-503 in Secondary (AA) AmyloidosisCompletedNCT00035334Phase 2/3